Beijing Tianli Zhengyuan Pharmaceutical Technology Development

Beijing Tianli Zhengyuan Pharmaceutical Technology Development is a Chinese biotechnology company focused on the research and development of innovative small molecule therapeutics, particularly for metabolic diseases. The company has advanced several candidates into clinical trials, including novel inhibitors targeting SGLT2 and DPP-4 for the treatment of type 2 diabetes. Their business model encompasses the full drug development lifecycle from discovery and preclinical evaluation to clinical trial management. Beijing Tianli Zhengyuan aims to provide high-quality, affordable pharmaceutical solutions to address significant unmet medical needs in the domestic Chinese market and beyond.